Market Overview

Myriad Says myPath Melanoma Test Highly Effective in Verification Study

Related MYGN
Myriad RBM DiscoveryMAP Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes
Crescendo Bioscience Vectra DA Data to be Presented at American College of Rheumatology 2015 Annual Meeting

Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that results from a verification study showed the Myriad myPath™ Melanoma test effectively differentiated malignant melanoma from benign skin lesions. The clinically-actionable information provided by myPath Melanoma will empower healthcare providers with objective data and improve the diagnosis of patients with melanoma. Myriad presented these data at the American Society of Dermatopathology Annual Meeting on Oct. 13, 2013.

The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The study analyzed 464 skin biopsy samples including 254 samples representing melanomas from all major subtypes including superficial spreading, lentigo maligna melanoma, acral, nodular and desmoplastic lesions. Using this set of patient samples, the myPath Melanoma test demonstrated high sensitivity of 89 percent and specificity of 93 percent at differentiating malignant melanoma from benign skin lesions.

Posted-In: News FDA


Related Articles (MYGN)

Get Benzinga's Newsletters